ramalingam compares third generation egfr tki osimertinib to older agents in nsclc
Published 4 years ago • 326 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:23
flaura trial demonstrates efficacy in egfr-positive lung cancer
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
4:48
third-generation egfr inhibitors in nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
0:49
exploring advantages to third-generation tkis in lung cancer
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
1:15
osimertinib improves survival in egfr nsclc, poses new challenges for resistance
-
8:30
third-generation egfr inhibitors in nsclc
-
4:39
defining osimertinib’s value in treating egfr nsclc
-
3:12
egfr-tki therapy in advanced nsclc
-
8:55
suresh ramalingam: osimertinib vs comparator egfr-tki 1st-line in egfrm advanced nsclc (flaura)
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
1:18
examining the combination of egfr inhibition plus chemotherapy in lung cancer
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
6:55
case 4: treating egfr nsclc after osimertinib